Cagrilintide half-life and pharmacokinetics chart
Pre-filled plasma half-life model for Cagrilintide. See how a 7.5 days half-life affects steady state, accumulation, peak-trough swing, and clearance timing.
Preset values: 2400 mcg every week, half-life ~7.5 days.
Long-acting amylin analog; ~180h half-life supports weekly dosing, often paired with semaglutide.
Open interactive chart →Why these values?
The half-life used here (7.5 days) is the published or well-established estimate for Cagrilintide from pharmacokinetic studies. The default dose (2400 mcg) and cadence (every week) reflect typical standard protocols — not a prescription or recommendation. Your specific product's label and your clinician's protocol override any default here.
Accumulation. With a half-life of 7.5 days and dosing every week, the ratio τ/t½ = 0.93 gives an accumulation factor of ~2.10×. That means the steady-state peak plasma mass is about 2.1× the mass of a single dose.
Time to steady state. Approximately 5 half-lives (~37.5 days) of consistent dosing before average concentration stops rising. Dose-escalation protocols that change doses before this point are titrating against a still-rising baseline, which is one reason weekly peptides feel "slow" at the start.
How long does Cagrilintide stay in your system?
After a single dose, half of the Cagrilintide is gone in about 7.5 days, 97% is cleared in about 38 days (five half-lives), and under 1% remains after about 50 days.
| Cleared | Remaining | Half-lives | Time after one Cagrilintide dose |
|---|---|---|---|
| 50% | 50% | 1 | 7.5 days |
| 75% | 25% | 2 | 15 days |
| 90% | 10% | 3.3 | 25 days |
| 97% | 3% | 5.1 | 38 days |
| 99% | 1% | 6.6 | 50 days |
Between doses. At every week, doses land 0.93 half-lives apart, so about 52% of the peak is still present when the next dose goes in. The steady-state swing in this model runs from ~5038 mcg at peak to ~2638 mcg at trough — a moderate swing with meaningful carry-over from one dose to the next.
A first-order, one-compartment model: it leaves out absorption delay from the injection depot, protein binding and individual differences in clearance, and effects can outlast plasma levels. Good for dosing rhythm; not clinical pharmacokinetics.
Cagrilintide half-life FAQ
What is the plasma half-life of Cagrilintide?
This chart uses an estimated Cagrilintide plasma half-life of about 7.5 days. Published values can vary by formulation, route, assay, and study design.
How long until Cagrilintide reaches steady state?
A simple first-order model reaches practical steady state after about five half-lives, which is roughly 37.5 days for Cagrilintide.
How long does Cagrilintide stay in your system?
After a single dose, half of the Cagrilintide is gone in about 7.5 days, 97% is cleared in about 38 days (five half-lives), and under 1% remains after about 50 days. Those are plasma estimates from a half-life of 7.5 days; effects can outlast plasma levels, and detection windows depend on the assay.
How much Cagrilintide is left when the next dose is due?
Dosing every week is 0.93 half-lives apart, so about 52% of the peak level remains at the next dose. At steady state that means a peak of ~5038 mcg and a trough of ~2638 mcg in the model.
Does this Cagrilintide pharmacokinetics chart recommend a dosing schedule?
No. It visualizes half-life, accumulation, peaks, and troughs from values you enter. It is not a prescription, dose recommendation, or substitute for the product label or clinician guidance.
Why does steady state matter for Cagrilintide?
Steady state explains why long-half-life compounds can keep rising for weeks after starting or changing a dose, while short-half-life compounds behave more like brief pulses.
Related for Cagrilintide
Half-life charts for related peptides: AOD-9604 (2 hours), Liraglutide (13 hours), MOTS-c (2 hours), Retatrutide (6 days).
Track your real Cagrilintide protocol
Peptide Protocol logs every actual injection time and shows your real timeline — not a model. Side-effect tracking included.
Get the iPhone app →Educational use only. Nothing on this page constitutes medical advice. Pharmacokinetic parameters are published estimates; individual PK varies. Use label values and consult a clinician for any dosing decision.
Educational use only. Peptide Protocol is an informational tool. Nothing on this page constitutes medical advice. Many peptides are prescription-only or restricted in your jurisdiction. Always consult a licensed healthcare professional before injecting any compound.